

Published in final edited form as:

*Exp Gerontol.* 2012 July ; 47(7): 483–490. doi:10.1016/j.exger.2012.03.020.

## Aging and dry eye disease

Juan Ding<sup>\*,1</sup> and David A. Sullivan<sup>1</sup>

<sup>1</sup>Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School 20 Staniford St., Boston, MA 02114, USA

### Abstract

Dry eye disease is a prevalent eye disorder that in particular affects the elderly population. One of the major causes of dry eye, meibomian gland dysfunction (MGD), shows increased prevalence with aging. MGD is caused by hyperkeratinization of the ductal epithelium of meibomian gland and reduced quantity and/or quality of meibum, the holocrine product that stabilizes and prevents the evaporation of the tear film. Of note, retinoids which are used in current anti-aging cosmetics may promote the development of MGD and dry eye disease. In this review, we will discuss the possible mechanisms of age-related MGD.

### Keywords

aging; meibomian gland dysfunction (MGD); dry eye disease; FOXO; retinoic acid; androgens; stem cell; growth hormone; insulin-like growth factor-1 (IGF-1); insulin sensitivity

### Introduction

The tear film plays an essential role in maintaining ocular surface integrity and health. It is structured in several layers that optimally maintain moisture on the ocular surface. The inner most is an underlying layer of glycocalyx that contains mucin, a highly glycosylated protein synthesized by the conjunctiva and cornea epithelial cells; a middle aqueous layer that is primarily secreted by lacrimal gland; and an overlying lipid layer that is released by the meibomian gland (Nichols and others 2011). The lipid layer prevents the evaporation of the tear film. Disruption or deficiency of the tear film causes increased sheer stress on the ocular surface that may lead to dry eye disease. If untreated, dry eye disease may result in perforation of the cornea, visual impairment and blindness (2007).

In the United States, it is estimated that 40 million people are affected by dry eye disease. Dry eye disease is classified into two types: aqueous-deficient and evaporative. The former is due to decreased tear secretion from the lacrimal gland, whereas the latter is caused primarily by meibomian gland dysfunction (MGD). One example of the aqueous -deficient dry eye is Sjögren's syndrome (SS), an autoimmune disease that affects approximately a million Americans. This disorder is associated with lymphocyte accumulation in lacrimal gland, an immune-mediated destruction and/or dysfunction of acinar and ductal epithelial

© 2012 Elsevier Inc. All rights reserved.

\*corresponding author: Juan Ding, Ph.D., Schepens Eye Research Institute, 20 Staniford St., Boston, MA 02114, USA, Juan.ding@schepens.harvard.edu, TEL: (617)-912-0288, Fax: (617)-912-0101.

**Conflict of interest:** The authors have no conflict of interest

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

cells, and a decline in aqueous tear output (2007). The second type, caused by MGD which also frequently occurs in SS, is believed to be the leading cause of dry eye disease worldwide (Nichols and others 2011). It is estimated that MGD is a contributing factor for over 2/3 of all dry eye cases (Shimazaki and others 1995). In one report, MGD accounted for 78% of dry eye patients (Horwath-Winter and others 2003). In Asian populations of adults older than 40yr, the prevalence of MGD is estimated to be 46.2-69.3%, although the prevalence is lower in caucasians of the same age group (Schaumberg and others 2011).

The evaporative dry eye, or MGD, is shown to have a strong positive correlation with aging (Den and others 2006; Hykin and Bron 1992; Schaumberg and others 2009; Schaumberg and others 2003; Sullivan and others 2006). In fact, aging is one of the major risk factors for MGD (Schaumberg and others 2011). Therefore the scope of this review will focus on MGD in aging research.

## Meibomian gland biology

The meibomian gland is a large sebaceous gland located in the eyelids (Figure 1). It was named after Heinrich Meibom, the German physician and anatomist who described this gland in detail in 1666. As a sebaceous gland, meibomian gland synthesizes and releases a mixture of lipids and proteins called meibum onto the ocular surface to prevent evaporation of the tears. Unlike other sebaceous glands, the meibomian gland is richly innervated and is not associated with hair follicles.

A single meibomian gland is composed of multiple secretory acini that are arranged circularly around a central duct, with the acini being connected to the central duct via short ductules (Figure 2A). The acinus is composed of secretory meibocytes that differentiate and mature until they become loaded with lipids in a hypermature state, upon which they disintegrate and release the whole cell content (meibum) in a holocrine manner. Meibum is released into the central duct where it moves toward the orifice (opening) on the lid margin and eventually to the ocular surface. Due to their holocrine nature, meibomian gland cells have to undergo constant renewal. New meibocytes emerge from the acinar periphery and differentiate (mature) as they migrate to the lateral duct of the meibomian gland and the cell content, meibum, released to the tear film.

It is believed that MGD is primarily caused by hyperkeratinization of the ductal epithelium and reduced quantity and/or quality of meibum (Knop and others 2011). On the one hand, obstruction causes low delivery of meibum to the ocular surface, causing evaporative dry eye. On the other hand, the obstruction of the duct by hyperkeratinization and/or viscous meibum causes accumulation of meibum within the ductal system due to the continuous secretion from the acini. Persistent meibum accumulation results in a progressive increase in pressure and thus widening of the ductal system including the small connecting ductules. This results in acinar atrophy with a loss of meibocytes and eventually a squamous metaplasia that may result in full cornification of the epithelia of the ducts and acini (Knop and others 2011). A comparison of the structure of normal and obstructed human meibomian gland is shown in Figure 2 (Knop and others 2009a; Knop and others 2011). The consequence is reduced meibum secretion and gland dropout, increased evaporation and hyperosmolarity of the tears, increased sheer stress, onset of inflammation at the ocular surface and unstable visual acuity (Knop and others 2011).

## MGD and aging in humans

As mentioned earlier, aging is a major risk factor for MGD. In a cross-sectional study involving 177 subjects aged 21-93yr, a significant association between abnormalities in the lid margin or meibomian glands and aging is observed (Den and others 2006). Another

cross-sectional study of 80 subjects aged 5-87yr found that lid margin vascularity, cutaneous hyperkeratinization and meibomian gland orifice narrowing increased with age (Hykin and Bron 1992). Aging in men and women is associated with a significant increase in lower lid erythema, telangiectasia, keratinization, irregular posterior margins, orifice metaplasia and opaque secretions (Sullivan and others 2006). The number of active meibomian glands also decrease by half from 20 to 80yr (Norn 1987) and gland dropout is visible at old age (Arita and others 2008). Histology of 83 human meibomian gland samples from 17-87yr at autopsy reveals acini atrophy, cystic dilatation of acini and/or ducts and basement membrane thickening of acini (Obata 2002).

Tear film break up time (TBUT), a clinical measurement of the tear stability, decreases with old age (Arita and others 2008; Sullivan and others 2006). Aging is also associated with significant changes in the lipid profiles of human meibomian gland secretions (Sullivan and others 2006). One type of lipid, cholesteryl esters, is significantly increased in adults compared to infants and children (Shrestha and others 2011). However, the significance of this related to MGD is not clear because MGD patients secrete meibum that contains lower levels of cholesteryl esters (Shrestha and others 2011). In terms of meibomian gland cells, recently, it has been shown that aging meibomian glands have decreased meibocyte differentiation and cell cycling (Nien and others 2011).

### **MGD and aging in animal studies**

There are very limited number of animal studies on MGD and aging. In one report, older mice (12 and 24 mo) showed less lipid content and acinar tissue atrophy compared to the young mice (2 and 6 mo) (Nien and others 2009). Further, the cellular location of peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ) was altered, indicating altered lipid synthesis, and reduced Ki67 nuclear staining indicative of reduced cycling cells in the old mice (Nien and others 2009).

### **Potential mechanisms of increased MGD with aging**

The mechanism of the age-related increase in MGD is not known. In fact, as discussed above, very few studies have been conducted on MGD in the context of aging at the mechanistic level. Interestingly, dry skin is often found in the elderly (White-Chu and Reddy 2011), suggesting a common aging phenomenon of meibomian gland and sebaceous gland. Based on available evidence in meibomian gland, sebaceous gland and a few other tissue types, several possible mechanisms are discussed below.

### **Androgens**

Androgens promote the lipid synthesis activity in sebocytes and meibocytes. Androgen receptors are expressed in sebocytes as well as meibocytes (Luderschmidt and others 1983; Rocha and others 2000). Androgens have been shown to regulate meibomian gland gene expression and lipid production (Krenzer and others 2000; Schirra and others 2006; Schirra and others 2007; Schirra and others 2005; Steagall and others 2002; Sullivan and others 2000). In particular, androgens stimulate genes in the lipid synthesis pathways in mouse meibomian gland (Schirra and others 2007; Schirra and others 2005). One of these genes is sterol regulatory element binding protein (SREBP), the most important known transcription factor for lipogenesis (Rosignoli and others 2003). Another androgen target gene is stearoyl-CoA desaturase-1 (scd-1), which is up-regulated by androgens in mouse meibomian glands of both sexes (Schirra and others 2005; Sullivan and others 2009). Scd-1 is an important enzyme in fatty acid metabolism, and Scd-1 null mice have severe atrophies of sebaceous and meibomian glands (Miyazaki and others 2001). This shows that androgens promote crucial genes for normal meibomian glands. Consistent with this, anti-androgen treatment is

associated with hyperkeratinization of the ductal epithelium, reduced meibum quality and MGD (Krenzer and others 2000; Sullivan and others 2002b). In complete androgen insensitivity syndrome (CAIS), significant alterations in polar and neutral lipids are found from meibomian gland secretions (Sullivan and others 2002a). Further, CAIS is associated with meibomian gland alterations and a significant increase in dry eye signs and symptoms, including significantly increased sensations of dryness, pain and light sensitivity, as well as a significant increase in telangiectasia, keratinization, lid erythema and orifice metaplasia of the meibomian glands, and a significant decrease in the tear meniscus and quality of meibomian gland secretions (Cermak and others 2003). Thus it is likely that age-related decline in androgens (Feldman and others 2002; Morley and others 1997) result in impaired lipid synthesis in meibomian gland cells, contributing to MGD at old age.

### Stem cell

Stem cells in adults are responsible for tissue renewal. In the case of meibomian gland, stem cells are particularly important because meibocytes are continuously lost via holocrine secretion. The stem cells of the meibomian gland are not well characterized. It was reported in one study that stem cells of the meibomian glands are located at the circumference of each acinus (Olami and others 2001). However, another study showed that slow cycling stem cells were located in the ductal epithelial cells (Lavker and others 2003). Regarding sebaceous gland, stem cells are located in the central bulge (Taylor and others 2000), or interfollicular epidermis (Lo Celso and others 2008). It is also suggested that multiple classes of stem cells independent of bulge exist (Ghazizadeh and Taichman 2001). At least three independent stem cell populations are present in the skin (Blanpain and Fuchs 2009). Analogous to the epidermis and hair-associated sebaceous glands, it has been proposed that the meibomian gland also has three independent stem cell populations: the progenitor cells at the acinar periphery (committed to lipid-producing meibocytes), at the basement membrane of the ductal epithelium (committed to ductal cells with physiological incipient keratinization) and at the epidermis of the excretory duct (committed to fully cornified epidermis of the skin) (Knop and others 2011).

Although it is not confirmed that stem cell aging is responsible for aging at the organism level (Rando 2006), aging is characterized by a reduced tissue regenerative potential due to changes in tissue-specific stem cells (Conboy and others 2005). Stem cells do not necessarily decrease in number or their proliferative capacity, but rather their function to produce progenitor cells that differentiate properly according to the appropriate cues may decline with age (Sharpless and DePinho 2007). Indeed changes have been found in stem cells at old compared to young ages. For example, hematopoietic stem cells in old mice are less efficient at homing to and engrafting the bone marrow of irradiated recipients (Morrison and others 1996). In terms of stem cells of the skin, it is thought that impaired stem cell mobilization or reduced number of stem cells able to respond to proliferative signals contributes to skin aging (Zouboulis and others 2008). Thus it is possible that in the meibomian gland acinar region, the potential of the stem cells to regenerate new functional meibocytes is impaired at an advanced age, resulting in gland dropout and reduced quantity and/or quality of meibum. Studies in humans and mice support the notion of a reduced functional stem cell pool at old age (Nien and others 2011; Nien and others 2009).

Further, stem cells committed to meibomian gland ductal cells and fully cornified epidermis at the free lid margin as discussed above may also be influenced by old age. Being a 'hair follicle without a hair shaft', meibomian gland ductal cells contain keratohyalin granules, show an incipient keratinization and preserve a commitment to keratinization (Knop and others 2009b). Thus it is possible that these stem cells, either by intrinsic aging or responding to an aging environment, differentiate into hyperkeratinized cells, leading to cutaneous hyperkeratinization, abnormal lid margin and meibomian gland orifice narrowing

commonly observed at old age (Den and others 2006; Hykin and Bron 1992; Sullivan and others 2006).

### **Growth hormone (GH)/Insulin-like growth factor-1 (IGF-1)**

GH, an important hormone regulating longitudinal body growth, stimulates the production of another hormone called IGF-1, which mediates some of GH's action for body growth. The GH/IGF-1 axis has been implicated in aging in animals as well as humans (Bartke 2011; Fontana and others 2010; Guevara-Aguirre and others 2011; List and others 2011; Shimokawa and others 2008). It is well known that an enhanced GH/IGF-1 axis causes premature aging in humans and mice (Chanson and Salenave 2008; Steger and others 1993; Wolf and others 1993) and conversely, diminished GH/IGF-1 axis as seen in GH receptor null mice results in increased lifespan (Coschigano and others 2003).

To date no study has been conducted on the effect of GH and IGF-1 on meibomian gland, although this gland may very well be regulated by both hormones, since both GH and IGF-1 receptor mRNAs are expressed in the mouse meibomian gland (Schirra and others 2005). GH/IGF-1 plays an important role in sebaceous gland development and growth (Deplewski and Rosenfield 2000), and acne peaks at puberty coinciding with the peak of GH/IGF-1 (Cara and others 1987). Further, acromegalic patients, who secrete excess GH due to pituitary adenomas, have increased acne (Burton and others 1972; Jabbour 2003). Specifically, GH induces the differentiation of sebocytes directly and also augments the androgen-induced sebocyte differentiation, whereas IGF-1 increases the sebocyte proliferation markedly (Deplewski and Rosenfield 1999). GH and IGF-1 levels decline during aging (HO and others 1987), possibly contributing to increased MGD as people age. This may seem paradoxical, given that increased GH/IGF-1 leads to premature aging (Chanson and Salenave 2008; Steger and others 1993; Wolf and others 1993). However, one major premise of this statement is the chronic hyperactive GH/IGF-1 axis as seen in acromegalic patients or GH transgenic mice, which is different from physiologically normal hormone levels that naturally decline as a function of age. In addition, aging at the organism level may not correlate completely with specific tissue aging.

### **Insulin sensitivity**

Insulin sensitivity has a close relationship with aging. Insulin resistance is generally found at old age (Rowe and others 1983) and insulin sensitivity is a hallmark of increased longevity (Masternak and others 2009). Given that MGD and insulin resistance are both found at old age, could it be that insulin resistance contributes to MGD? To date no study has been conducted on the relationship between insulin sensitivity and MGD. Related to sebaceous gland, dry skin has been observed in morbidly obese people (Yosipovitch and others 2007), although it is not known whether this is due to reduced sebaceous gland activity or other dermatological issues. On the other hand, increased acne is associated with obesity-associated disorders including hyperandrogenism, and hirsutism and polycystic ovary syndrome (Yosipovitch and others 2007); however, these are complicated by the primary involvement of sex hormones. It will be interesting to see the clinical manifestations of sebaceous gland and meibomian gland activities in patients with obesity, insulin resistance or type II diabetes.

In the insulin sensitive state, insulin stimulation results in glucose uptake and synthesis of lipids as an energy reservoir. Insulin resistance is characterized with reduced response to insulin signaling, including lipogenesis. Insulin signaling activates a key transcription factor in lipogenesis, peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ), which is required to promote adipocyte differentiation in vitro and in vivo (Rosen and others 1999). PPAR $\gamma$  also promotes sebaceous gland differentiation and lipogenesis as well as sebum secretion (Fu and

others 2010; Rosenfield and others 2000; Trivedi and others 2006). In terms of meibomian gland, PPAR $\gamma$  coincides with mouse meibocyte differentiation and lipid synthesis (Nien and others 2010) during development, and altered PPAR $\gamma$  staining accompanied reduced lipid accumulation in both human and mouse meibomian glands with aging (Nien and others 2011; Nien and others 2009). These data show reduced PPAR $\gamma$  activity in the aged meibomian gland, which seems to be consistent with one aspect of insulin resistance. Research is needed to reveal a relationship between insulin resistance and MGD.

### Converging signal: FOXOs

Recent advances have shown emerging cell signaling pathways in aging and age-related diseases such as cancer and diabetes. One of these pathways involves insulin/IGF-1 signaling dependent inhibition of forkhead box O1 (FoxO1). Insulin/IGF-1 activates a downstream signaling cascade of phosphoinositide 3-kinase (PI3K) and protein kinase B (PKB, also known as AKT), leading to activation of FoxO transcription factors that activate or suppress an array of target genes (Figure 3).

FoxO transcription factors including FoxO1 (the most abundant isoform), FoxO3a, FoxO4 and FoxO6 regulate genes involved in cell cycle control, apoptosis, cell differentiation and stem cell homeostasis (Huang and Tindall 2007; van der Vos and Coffey 2011). The importance of these transcription factors may be apparent from genetic disruption of these genes in mice. FoxO1 null mice are embryonically lethal due to incomplete vascular development, whereas FoxO3a null mice show age-dependent female infertility and FoxO4 null mice appear normal (Hosaka and others 2004). FoxOs normally reside in the nucleus and function as transcription factors, but when stimulated by growth factors such as insulin and IGF-1, they become phosphorylated and translocate from the nucleus to the cytosol thereby losing their activity as transcription factors (Huang and Tindall 2007). On the other hand, deacetylation by silent mating type information regulation 2 homolog-1 (SIRT1) promotes the activity of FoxO1 in transcribing genes involved in cell cycle arrest (Brunet and others 2004).

During aging, insulin resistance and/or declined GH/IGF-1 axis as discussed above may result in reduced insulin/IGF-1 signaling, leading to activated FoxOs (Figure 3). FoxOs potentially regulate meibocytes via two ways: 1) inducing cell cycle arrest and apoptosis, and 2) inhibiting lipogenesis. FoxOs are known to induce apoptosis in various cell types (Essaghir and others 2009; Huang and Tindall 2007; Kops and others 2002; Sakoe and others 2010). FoxOs reduce DNA synthesis, induce G1/S cell cycle arrest, as well as regulate key genes in cell cycle (Essaghir and others 2009; Huang and Tindall 2007; Kops and others 2002; Sakoe and others 2010). FoxOs inhibit lipogenesis (Cheng and White 2011) and are known to regulate lipid metabolism via three pathways: PPARs, androgen receptor and SREBP. As noted above, PPARs are important regulators for lipogenesis for many cell types including the sebocytes (Makrantonaki and Zouboulis 2007). Agonists of PPAR isoforms ( $\alpha$ ,  $\delta$  and  $\gamma$ ) promote sebocyte differentiation. Of the three isoforms, PPAR $\gamma$  is the most important in lipogenesis of sebaceous gland. PPAR $\gamma$  heterodimerizes with retinoid X receptor (RXR) and binds to PPAR response elements (PPRE) in the promoters of target genes. FoxO1 inhibits PPAR $\gamma$  by blocking its activity and reducing its levels. For example, FoxO1 directly binds and represses PPAR $\gamma$  promoter and PPAR $\gamma$  function in primary rat adipocytes and *Caenorhabditis elegans* (Armoni and others 2006; Dowell and others 2003). In addition, FoxO1 down-regulates the expression of PPAR $\gamma$  by acting as a co-repressor at the promoter of PPAR $\gamma$  (Melnik 2011). Androgens promote lipid production as discussed earlier. FoxO1 reduces the expression of androgen receptor (Fan and others 2007; Ma and others 2009), interacts with androgen receptor and suppresses its target genes including SREBP. Further, FoxO1 directly suppresses the promoter of SREBP, leading to reduced lipid synthesis (Melnik 2011). However, the known effects of FoxO1 in

apoptosis, cell cycle and lipid metabolism regulation are yet to be demonstrated in meibomian gland cells. Lastly, FoxO1 regulates stem cell homeostasis. Targeted disruption of FoxO1, FoxO3 and FoxO4 in the mouse hematopoietic system resulted in increased short-term repopulation activity of the stem cells; however, in the long term, population of hematopoietic stem cells (HSC) were decreased, indicating that FoxOs are important in maintaining the HSC quiescence, thereby preserving their self-renewal capacity (Tothova and others 2007). It is therefore conceivable that if FoxO activity increases at old age, it will similarly keep stem cells in a quiescent state (Figure 3), even though FoxO activity is required at younger ages to prevent fast turnover and depletion of the stem cell pool. Thus FoxOs may show an antagonistic pleiotropic effect during aging.

### Anti-aging treatment- potential influence on MGD and dry eye

It is of great interest for many to turn back the clock and look youthful, if only for the appearance. In the market of anti-aging products for skin, one touted active ingredient is retinoic acid (RA) and its derivatives (retinoids) (Levin and Momin 2010). Retinoids are thought to reduce hyperpigmentation and skin roughness by enhancing epidermal cell turnover, and reduce fine lines and wrinkles by stimulating glycosaminoglycan and collagen synthesis and inhibiting enzymes that degrade collagen (Sorg and others 2005). These effects are thought to be mediated by retinoic acid receptor (RAR) (Sorg and others 2005). Even though randomized, double blind, placebo-controlled clinical studies on the anti-aging efficacy of retinoids are scarce and lack statistical confirmation (Levin and Momin 2010), this does not thwart the fast growing market for RA-based anti-aging cosmetics. Anti-aging skin care products, of which retinoids-based products are a major component, showed an annual growth rate of 11.8% from 2002-2007 and 9.7% from 2007-2012, far exceeding all the other skin care products combined (Brandt and others 2011). Unfortunately one side effect of RA cream is dryness of the skin. In fact, 13-cis retinoic acid (13-cis RA), also known as isotretinoin or Accutane, was initially used to treat acne before it found its way into the anti-aging cosmetics. It is highly effective in reducing sebaceous gland size by inhibiting sebocyte proliferation, differentiation and sebum production (Zouboulis 2006). Not surprisingly, RA causes MGD and dry eye disease, given that meibomian gland is a sebaceous gland. RA causes keratinization and thickening of the meibomian gland ducts (Lambert and Smith 1989), degeneration and necrosis of the acinar cells (Kremer and others 1994), fibrosis of the periacinar tissue, and reduced lipid content in meibomian gland (Lambert and Smith 1989). Further, isotretinoin exposure is associated with tear film instability and hyperosmolarity, dry eye symptoms and blepharitis (Bozkurt and others 2002; Fraunfelder 2004; Karalezli and others 2009; Santodomingo-Rubido and others 2008). In effect, RA promotes MGD and evaporative dry eye disease (Knop and others 2011).

In the sebaceous gland, RA decreases basal sebocyte proliferation, prohibits sebocyte terminal differentiation, induces sebocyte apoptosis, and suppresses sebum production up to 90% (Nelson and others 2006). These effects appear to be mediated through receptor-dependent and -independent actions (Nelson and others 2006; Tsukada and others 2000) and alterations in gene expression (Nelson and others 2008). In addition, RA may suppress androgen receptors (Ubels and others 2003; Ubels and others 2002) and inhibit retinol dehydrogenase-4 in sebaceous glands (Karlsson and others 2003), which would diminish the local, intracrine production of dihydrotestosterone (DHT). Of interest, specific deletion of *scd-1* in the mouse skin causes a robust elevation of retinol, RA and RA-induced genes in the skin (Flowers and others 2011). This indicates that not only does RA inhibit androgen action in the sebaceous gland, but disruption of an important androgen target gene also leads to enhanced RA activity, therefore androgens and RA have antagonistic actions in the sebaceous gland. By analogy, these actions of RA would similarly attenuate androgen activity in meibomian gland and lead to MGD.

Another anti-aging agent that has attracted a lot of attention is resveratrol, a polyphenol found in red wine and a variety of fruits and plants, that has protective effects against age-related diseases in rodents (Baur and Sinclair 2006) and multiple potential health benefits in humans (Smoliga and others 2011). Recently it was used in a pilot study to treat acne, with positive results (Fabbrocini and others 2011). The mechanism of this is not yet known, but if the effect is mediated through the suppression of sebaceous gland, potentially a similar effect can be seen in meibomian gland.

Interestingly, RA is known to activate FoxO3a in several cell systems (Kim and others 2009; Sakoe and others 2010); and resveratrol also activates FoxO1 in various cells (Chen and others 2010; Costa Cdos and others 2011; Niu and others 2011; Park and others 2010; Roy and others 2011), in part through activation of SIRT1 (Feige and others 2008), an NAD(+)-dependent deacetylase that has been recognized as a conserved regulator of aging (Satoh and others 2011). Therefore it is possible that RA and resveratrol exert their therapeutic effects on acne mediated by FoxOs in the sebaceous gland and meibomian gland (Figure 3), which in the meibomian gland could be a potential mechanism of RA-induced MGD and dry eye disease.

## Conclusion

Dry eye disease is a prevalent eye disorder affecting many people worldwide. The evaporative subtype is primarily caused by MGD, with aging being a risk factor. MGD is a relatively new field in ophthalmological research (Nichols 2011) and hence not well-studied. Although the association of aging with MGD/dry eye disease has long been recognized, very few studies have been done to address the mechanism of age-related increase of MGD. Potentially relevant mechanisms include androgens, GH/IGF-1 axis, stem cell and insulin resistance, with one converging signal of FOXOs. One pertinent health problem is that certain anti-aging treatments may actually adversely affect MGD and lead to dry eye disease. Studies are needed to unravel the mechanism of age-related MGD in order to permit the development of safe and effective therapeutics.

## Acknowledgments

We thank the funding support from the National Institutes of Health (NIH R01 EY05612); JD is also supported by AFER/Vistakon Dry Eye Fellowship.

## References

- The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). *The ocular surface*. 2007; 5:75–92. [PubMed: 17508116]
- Arita R, Itoh K, Inoue K, Amano S. Noncontact infrared meibography to document age-related changes of the meibomian glands in a normal population. *Ophthalmology*. 2008; 115:911–915. [PubMed: 18452765]
- Armoni M, Harel C, Karni S, Chen H, Bar-Yoseph F, Ver MR, Quon MJ, Karnieli E. FOXO1 represses peroxisome proliferator-activated receptor- $\gamma$ 1 and - $\gamma$ 2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity. *The Journal of biological chemistry*. 2006; 281:19881–19891.
- Bartke A. Growth hormone, insulin and aging: the benefits of endocrine defects. *Experimental gerontology*. 2011; 46:108–111. [PubMed: 20851173]
- Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. *Nature reviews Drug discovery*. 2006; 5:493–506.
- Blanpain C, Fuchs E. Epidermal homeostasis: a balancing act of stem cells in the skin. *Nature reviews Molecular cell biology*. 2009; 10:207–217.



- Bozkurt B, Irkec MT, Atakan N, Orhan M, Geyik PO. Lacrimal function and ocular complications in patients treated with systemic isotretinoin. *European journal of ophthalmology*. 2002; 12:173–176. [PubMed: 12113560]
- Brandt FS, Cazzaniga A, Hann M. Cosmeceuticals: Current Trends and Market Analysis. *Seminars in Cutaneous Medicine and Surgery*. 2011; 30:141–143. [PubMed: 21925366]
- Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, Greenberg ME. Stress-Dependent Regulation of FOXO Transcription Factors by the SIRT1 Deacetylase. *Science*. 2004; 303:2011. [PubMed: 14976264]
- Burton JL, Libman LJ, Cunliffe WJ, Wilkinson R, Hall R, Shuster S. Sebum excretion in acromegaly. *British medical journal*. 1972; 1:406–408. [PubMed: 4333483]
- Cara JF, Rosenfield RL, Furlanetto RW. A longitudinal study of the relationship of plasma somatomedin-C concentration to the pubertal growth spurt. *Am J Dis Child*. 1987; 141:562–564. [PubMed: 3578171]
- Cermak JM, Krenzer KL, Sullivan RM, Dana MR, Sullivan DA. Is complete androgen insensitivity syndrome associated with alterations in the meibomian gland and ocular surface? *Cornea*. 2003; 22:516–521. [PubMed: 12883343]
- Chanson P, Salenave S. Acromegaly. *Orphanet J Rare Dis*. 2008; 3:17. [PubMed: 18578866]
- Chen Q, Ganapathy S, Singh KP, Shankar S, Srivastava RK. Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. *PLoS ONE*. 2010; 5:e15288. [PubMed: 21179458]
- Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. *Nature*. 2005; 433:760–764. [PubMed: 15716955]
- Coschigano KT, Holland AN, Riders ME, List EO, Flyvbjerg A, Kopchick JJ. Deletion, But Not Antagonism, of the Mouse Growth Hormone Receptor Results in Severely Decreased Body Weights, Insulin, and Insulin-Like Growth Factor I Levels and Increased Life Span 10.1210/en.2003-0374. *Endocrinology*. 2003; 144:3799–3810. [PubMed: 12933651]
- Costa Cdos S, Rohden F, Hammes TO, Margis R, Bortolotto JW, Padoin AV, Mottin CC, Guaragna RM. Resveratrol upregulated SIRT1, FOXO1, and adiponectin and downregulated PPARgamma1-3 mRNA expression in human visceral adipocytes. *Obesity surgery*. 2011; 21:356–361. [PubMed: 20872255]
- Den S, Shimizu K, Ikeda T, Tsubota K, Shimmura S, Shimazaki J. Association between meibomian gland changes and aging, sex, or tear function. *Cornea*. 2006; 25:651–655. [PubMed: 17077655]
- Deplewski D, Rosenfield RL. Growth hormone and insulin-like growth factors have different effects on sebaceous cell growth and differentiation. *Endocrinology*. 1999; 140:4089–4094. [PubMed: 10465280]
- Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. *Endocrine reviews*. 2000; 21:363–392. [PubMed: 10950157]
- Dowell P, Otto TC, Adi S, Lane MD. Convergence of peroxisome proliferator-activated receptor gamma and Foxo1 signaling pathways. *The Journal of biological chemistry*. 2003; 278:45485–45491. [PubMed: 12966085]
- Essagher A, Dif N, Marbehant CY, Coffey PJ, Demoulin JB. The transcription of FOXO genes is stimulated by FOXO3 and repressed by growth factors. *The Journal of biological chemistry*. 2009; 284:10334–10342. [PubMed: 19244250]
- Fabbrocini G, Staibano S, De Rosa G, Battimiello V, Fardella N, Iardi G, La Rotonda MI, Longobardi A, Mazzella M, Siano M, Pastore F, De Vita V, Vecchione ML, Ayala F. Resveratrol-containing gel for the treatment of acne vulgaris: a single-blind, vehicle-controlled, pilot study. *American journal of clinical dermatology*. 2011; 12:133–141. [PubMed: 21348544]
- Fan W, Yanase T, Morinaga H, Okabe T, Nomura M, Daitoku H, Fukamizu A, Kato S, Takayanagi R, Nawata H. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. *The Journal of biological chemistry*. 2007; 282:7329–7338. [PubMed: 17202144]

- Feige JN, Lagouge M, Canto C, Strehle A, Houten SM, Milne JC, Lambert PD, Matakis C, Elliott PJ, Auwerx J. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. *Cell metabolism*. 2008; 8:347–358. [PubMed: 19046567]
- Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. *The Journal of clinical endocrinology and metabolism*. 2002; 87:589–598. [PubMed: 11836290]
- Flowers MT, Paton CM, O'Byrne SM, Schiesser K, Dawson JA, Blaner WS, Kendzierski C, Ntambi JM. Metabolic changes in skin caused by Scd1 deficiency: a focus on retinol metabolism. *PLoS ONE*. 2011; 6:e19734. [PubMed: 21573029]
- Fontana L, Partridge L, Longo VD. Extending healthy life span--from yeast to humans. *Science*. 2010; 328:321–326. [PubMed: 20395504]
- Fraunfelder FW. Ocular side effects associated with isotretinoin. *Drugs Today (Barc)*. 2004; 40:23–27. [PubMed: 14988767]
- Fu G, Gao QG, Lian XH, Yu J, Xiang MM, Yang T. Committed differentiation of hair follicle bulge cells into sebocytes: an in vitro study. *International journal of dermatology*. 2010; 49:135–140. [PubMed: 20465636]
- Ghazizadeh S, Taichman LB. Multiple classes of stem cells in cutaneous epithelium: a lineage analysis of adult mouse skin. *The EMBO journal*. 2001; 20:1215–1222. [PubMed: 11250888]
- Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, Hwang D, Martin-Montalvo A, Saavedra J, Ingles S, de Cabo R, Cohen P, Longo VD. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. *Science translational medicine*. 2011; 3:70ra13.
- HO KY, Evans WS, Blizzard RM, Veldhuis JD, Merriam GR, Samojlik E, Furlanetto R, Rogol AD, Kaiser DL, Thorner MO. Effects of Sex and Age on the 24-Hour Profile of Growth Hormone Secretion in Man: Importance of Endogenous Estradiol Concentrations. *Journal of Clinical Endocrinology & Metabolism*. 1987; 64:51–58. [PubMed: 3782436]
- Horwath-Winter J, Berghold A, Schmut O, Floegel I, Solhdju V, Bodner E, Schwantzer G, Haller-Schober EM. Evaluation of the clinical course of dry eye syndrome. *Archives of ophthalmology*. 2003; 121:1364–1368. [PubMed: 14557170]
- Hosaka T, Biggs WH, Tieu D, Boyer AD, Varki NM, Cavenee WK, Arden KC. Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. *Proc Natl Acad Sci U S A*. 2004; 101:2975–2980. [PubMed: 14978268]
- Huang H, Tindall DJ. Dynamic FoxO transcription factors. *Journal of cell science*. 2007; 120:2479–2487. [PubMed: 17646672]
- Hykin PG, Bron AJ. Age-related morphological changes in lid margin and meibomian gland anatomy. *Cornea*. 1992; 11:334–342. [PubMed: 1424655]
- Jabbour SA. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. *American journal of clinical dermatology*. 2003; 4:315–331. [PubMed: 12688837]
- Karalezli A, Borazan M, Altinors DD, Dursun R, Kiyici H, Akova YA. Conjunctival impression cytology, ocular surface, and tear-film changes in patients treated with systemic isotretinoin. *Cornea*. 2009; 28:46–50. [PubMed: 19092405]
- Karlsson T, Vahlquist A, Kedishvili N, Torma H. 13-cis-retinoic acid competitively inhibits 3 alpha-hydroxysteroid oxidation by retinol dehydrogenase RoDH-4: a mechanism for its anti-androgenic effects in sebaceous glands? *Biochemical and biophysical research communications*. 2003; 303:273–278. [PubMed: 12646198]
- Kim MJ, Ahn K, Park SH, Kang HJ, Jang BG, Oh SJ, Oh SM, Jeong YJ, Heo JI, Suh JG, Lim SS, Ko YJ, Huh SO, Kim SC, Park JB, Kim J, Kim JI, Jo SA, Lee JY. SIRT1 regulates tyrosine hydroxylase expression and differentiation of neuroblastoma cells via FOXO3a. *FEBS letters*. 2009; 583:1183–1188. [PubMed: 19285077]
- Knop E, Knop N, Brewitt H, Pleyer U, Rieck P, Seitz B, Schirra F. Meibomian glands : part III. Dysfunction - argument for a discrete disease entity and as an important cause of dry eye. *Der*

- Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2009a; 106:966–979. [PubMed: 19941140]
- Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. *Investigative ophthalmology & visual science*. 2011; 52:1938–1978. [PubMed: 21450915]
- Knop E, Ludescher M, Knop N. Keratinisation status and cytokeratins of the human Meibomian gland epithelium. *Acta ophthalmologica*. 2009b; 87:0–0.
- Kops GJ, Medema RH, Glassford J, Essers MA, Dijkers PF, Coffey PJ, Lam EW, Burgering BM. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. *Molecular and cellular biology*. 2002; 22:2025–2036. [PubMed: 11884591]
- Kremer I, Gatton DD, David M, Gatton E, Shapiro A. Toxic effects of systemic retinoids on meibomian glands. *Ophthalmic research*. 1994; 26:124–128. [PubMed: 8196934]
- Krenzer KL, Dana MR, Ullman MD, Cermak JM, Tolls DB, Evans JE, Sullivan DA. Effect of androgen deficiency on the human meibomian gland and ocular surface. *The Journal of clinical endocrinology and metabolism*. 2000; 85:4874–4882. [PubMed: 11134156]
- Lambert RW, Smith RE. Effects of 13-cis-retinoic acid on the hamster meibomian gland. *The Journal of investigative dermatology*. 1989; 92:321–325. [PubMed: 2918239]
- Lavker RM, Treet J, Sun T. Label-retaining Cells (LRCs) Are Preferentially Located in the Ductal Epithelium of the Meibomian Gland: Implications on the Mucocutaneous Junctional (MCJ) Epithelium of the Eyelid. *Invest Ophthalmol Vis Sci*. 2003; 44:3781.
- Levin J, Momin SB. How much do we really know about our favorite cosmeceutical ingredients? *The Journal of clinical and aesthetic dermatology*. 2010; 3:22–41. [PubMed: 20725560]
- List EO, Sackmann-Sala L, Berryman DE, Funk K, Kelder B, Gosney ES, Okada S, Ding J, Cruz-Topete D, Kopchick JJ. Endocrine parameters and phenotypes of the growth hormone receptor gene disrupted (GHR<sup>-/-</sup>) mouse. *Endocrine reviews*. 2011; 32:356–386. [PubMed: 21123740]
- Lo Celso C, Berta MA, Braun KM, Frye M, Lyle S, Zouboulis CC, Watt FM. Characterization of bipotential epidermal progenitors derived from human sebaceous gland: contrasting roles of c-Myc and beta-catenin. *Stem Cells*. 2008; 26:1241–1252. [PubMed: 18308950]
- Luderschmidt C, Eiermann W, Jawny J. Steroid hormone receptors and their relevance for sebum production in the sebaceous gland ear model of the Syrian hamster. *Archives of dermatological research*. 1983; 275:175–180. [PubMed: 6614993]
- Ma Q, Fu W, Li P, Nicosia SV, Jenster G, Zhang X, Bai W. FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment. *Mol Endocrinol*. 2009; 23:213–225. [PubMed: 19074551]
- Makrantonaki E, Zouboulis CC. Testosterone metabolism to 5alpha-dihydrotestosterone and synthesis of sebaceous lipids is regulated by the peroxisome proliferator-activated receptor ligand linoleic acid in human sebocytes. *The British journal of dermatology*. 2007; 156:428–432. [PubMed: 17300229]
- Masternak MM, Panici JA, Bonkowski MS, Hughes LF, Bartke A. Insulin sensitivity as a key mediator of growth hormone actions on longevity. *The journals of gerontology Series A, Biological sciences and medical sciences*. 2009; 64:516–521.
- Melnik BC. Isotretinoin and FoxO1: A scientific hypothesis. *Dermato-endocrinology*. 2011; 3:141–165. [PubMed: 22110774]
- Miyazaki M, Man WC, Ntambi JM. Targeted disruption of stearyl-CoA desaturase1 gene in mice causes atrophy of sebaceous and meibomian glands and depletion of wax esters in the eyelid. *The Journal of nutrition*. 2001; 131:2260–2268. [PubMed: 11533264]
- Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Morley PM, Stauber PM, Vellas B, Baumgartner RN, Garry PJ. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. *Metabolism: clinical and experimental*. 1997; 46:410–413. [PubMed: 9109845]
- Morrison SJ, Wandycz AM, Akashi K, Globerson A, Weissman IL. The aging of hematopoietic stem cells. *Nature medicine*. 1996; 2:1011–1016.

- Nelson AM, Gilliland KL, Cong Z, Thiboutot DM. 13-cis Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. *The Journal of investigative dermatology*. 2006; 126:2178–2189. [PubMed: 16575387]
- Nelson AM, Zhao W, Gilliland KL, Zaenglein AL, Liu W, Thiboutot DM. Neutrophil gelatinase-associated lipocalin mediates 13-cis retinoic acid-induced apoptosis of human sebaceous gland cells. *The Journal of clinical investigation*. 2008; 118:1468–1478. [PubMed: 18317594]
- Nichols KK. The international workshop on meibomian gland dysfunction: introduction. *Investigative ophthalmology & visual science*. 2011; 52:1917–1921. [PubMed: 21450912]
- Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, Lemp MA, Sullivan DA. The international workshop on meibomian gland dysfunction: executive summary. *Investigative ophthalmology & visual science*. 2011; 52:1922–1929. [PubMed: 21450913]
- Nien CJ, Massei S, Lin G, Liu H, Paugh JR, Liu CY, Kao WW, Brown DJ, Jester JV. The development of meibomian glands in mice. *Molecular vision*. 2010; 16:1132–1140. [PubMed: 20664693]
- Nien CJ, Massei S, Lin G, Nabavi C, Tao J, Brown DJ, Paugh JR, Jester JV. Effects of age and dysfunction on human meibomian glands. *Archives of ophthalmology*. 2011; 129:462–469. [PubMed: 21482872]
- Nien CJ, Paugh JR, Massei S, Wahlert AJ, Kao WW, Jester JV. Age-related changes in the meibomian gland. *Experimental eye research*. 2009; 89:1021–1027. [PubMed: 19733559]
- Niu XF, Liu BQ, Du ZX, Gao YY, Li C, Li N, Guan Y, Wang HQ. Resveratrol protects leukemic cells against cytotoxicity induced by proteasome inhibitors via induction of FOXO1 and p27Kip1. *BMC cancer*. 2011; 11:99. [PubMed: 21418583]
- Norn M. Expressibility of meibomian secretion. Relation to age, lipid precorneal film, scales, foam, hair and pigmentation. *Acta ophthalmologica*. 1987; 65:137–142. [PubMed: 3604602]
- Obata H. Anatomy and histopathology of human meibomian gland. *Cornea*. 2002; 21:S70–74. [PubMed: 12484702]
- Olami Y, Zajicek G, Cogan M, Gnessin H, Pe'er J. Turnover and migration of meibomian gland cells in rats' eyelids. *Ophthalmic research*. 2001; 33:170–175. [PubMed: 11340409]
- Park JM, Kim TH, Bae JS, Kim MY, Kim KS, Ahn YH. Role of resveratrol in FOXO1-mediated gluconeogenic gene expression in the liver. *Biochemical and biophysical research communications*. 2010; 403:329–334. [PubMed: 21078299]
- Rando TA. Stem cells, ageing and the quest for immortality. *Nature*. 2006; 441:1080–1086. [PubMed: 16810243]
- Rocha EM, Wickham LA, da Silveira LA, Krenzer KL, Yu FS, Toda I, Sullivan BD, Sullivan DA. Identification of androgen receptor protein and 5alpha-reductase mRNA in human ocular tissues. *The British journal of ophthalmology*. 2000; 84:76–84. [PubMed: 10611104]
- Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. *Molecular cell*. 1999; 4:611–617. [PubMed: 10549292]
- Rosenfield RL, Deplewski D, Greene ME. Peroxisome proliferator-activated receptors and skin development. *Hormone research*. 2000; 54:269–274. [PubMed: 11595816]
- Rosignoli C, Nicolas JC, Jomard A, Michel S. Involvement of the SREBP pathway in the mode of action of androgens in sebaceous glands in vivo. *Experimental dermatology*. 2003; 12:480–489. [PubMed: 12930306]
- Rowe JW, Minaker KL, Pallotta JA, Flier JS. Characterization of the insulin resistance of aging. *The Journal of clinical investigation*. 1983; 71:1581–1587. [PubMed: 6345585]
- Roy SK, Chen Q, Fu J, Shankar S, Srivastava RK. Resveratrol Inhibits Growth of Orthotopic Pancreatic Tumors through Activation of FOXO Transcription Factors. *PLoS ONE*. 2011; 6:e25166. [PubMed: 21980390]
- Sakoe Y, Sakoe K, Kirito K, Ozawa K, Komatsu N. FOXO3A as a key molecule for all-trans retinoic acid-induced granulocytic differentiation and apoptosis in acute promyelocytic leukemia. *Blood*. 2010; 115:3787–3795. [PubMed: 20215638]
- Santodomingo-Rubido J, Barrado-Navascues E, Rubido-Crespo MJ. Drug-induced ocular side-effects with isotretinoin. *Ophthalmic Physiol Opt*. 2008; 28:497–501. [PubMed: 18761487]

- Satoh A, Stein L, Imai S. The role of mammalian sirtuins in the regulation of metabolism, aging, and longevity. *Handbook of experimental pharmacology*. 2011; 206:125–162. [PubMed: 21879449]
- Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies. *Archives of ophthalmology*. 2009; 127:763–768. [PubMed: 19506195]
- Schaumberg DA, Nichols JJ, Papas EB, Tong L, Uchino M, Nichols KK. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. *Investigative ophthalmology & visual science*. 2011; 52:1994–2005. [PubMed: 21450917]
- Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. *American journal of ophthalmology*. 2003; 136:318–326. [PubMed: 12888056]
- Schirra F, Richards SM, Liu M, Suzuki T, Yamagami H, Sullivan DA. Androgen regulation of lipogenic pathways in the mouse meibomian gland. *Experimental eye research*. 2006; 83:291–296. [PubMed: 16579987]
- Schirra F, Richards SM, Sullivan DA. Androgen influence on cholesterogenic enzyme mRNA levels in the mouse meibomian gland. *Current eye research*. 2007; 32:393–398. [PubMed: 17514523]
- Schirra F, Suzuki T, Richards SM, Jensen RV, Liu M, Lombardi MJ, Rowley P, Treister NS, Sullivan DA. Androgen control of gene expression in the mouse meibomian gland. *Investigative ophthalmology & visual science*. 2005; 46:3666–3675. [PubMed: 16186348]
- Sharpless NE, DePinho RA. How stem cells age and why this makes us grow old. *Nature reviews Molecular cell biology*. 2007; 8:703–713.
- Shimazaki J, Sakata M, Tsubota K. Ocular surface changes and discomfort in patients with meibomian gland dysfunction. *Archives of ophthalmology*. 1995; 113:1266–1270. [PubMed: 7575257]
- Shimokawa I, Chiba T, Yamaza H, Komatsu T. Longevity genes: insights from calorie restriction and genetic longevity models. *Mol Cells*. 2008; 26:427–435. [PubMed: 18799928]
- Shrestha RK, Borchman D, Foulks GN, Yappert MC, Milliner SE. Analysis of the composition of lipid in human meibum from normal infants, children, adolescents, adults, and adults with meibomian gland dysfunction using (1)H-NMR spectroscopy. *Investigative ophthalmology & visual science*. 2011; 52:7350–7358. [PubMed: 21849420]
- Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health – A comprehensive review of human clinical trials. *Molecular Nutrition & Food Research*. 2011; 55:1129–1141. [PubMed: 21688389]
- Sorg O, Kuenzli S, Kaya G, Saurat JH. Proposed mechanisms of action for retinoid derivatives in the treatment of skin aging. *Journal of cosmetic dermatology*. 2005; 4:237–244. [PubMed: 17168870]
- Steagall RJ, Yamagami H, Wickham LA, Sullivan DA. Androgen control of gene expression in the rabbit meibomian gland. *Advances in experimental medicine and biology*. 2002; 506:465–476. [PubMed: 12613947]
- Steger RW, Bartke A, Cecim M. Premature ageing in transgenic mice expressing different growth hormone genes. *J Reprod Fertil Suppl*. 1993; 46:61–75. [PubMed: 8100276]
- Sullivan BD, Evans JE, Cermak JM, Krenzer KL, Dana MR, Sullivan DA. Complete androgen insensitivity syndrome: effect on human meibomian gland secretions. *Archives of ophthalmology*. 2002a; 120:1689–1699. [PubMed: 12470144]
- Sullivan BD, Evans JE, Dana MR, Sullivan DA. Impact of androgen deficiency on the lipid profiles in human meibomian gland secretions. *Advances in experimental medicine and biology*. 2002b; 506:449–458. [PubMed: 12613945]
- Sullivan BD, Evans JE, Dana MR, Sullivan DA. Influence of aging on the polar and neutral lipid profiles in human meibomian gland secretions. *Archives of ophthalmology*. 2006; 124:1286–1292. [PubMed: 16966624]
- Sullivan DA, Jensen RV, Suzuki T, Richards SM. Do sex steroids exert sex-specific and/or opposite effects on gene expression in lacrimal and meibomian glands? *Molecular vision*. 2009; 15:1553–1572. [PubMed: 19693291]
- Sullivan DA, Sullivan BD, Ullman MD, Rocha EM, Krenzer KL, Cermak JM, Toda I, Doane MG, Evans JE, Wickham LA. Androgen influence on the meibomian gland. *Investigative ophthalmology & visual science*. 2000; 41:3732–3742. [PubMed: 11053270]

- Taylor G, Lehrer MS, Jensen PJ, Sun TT, Lavker RM. Involvement of follicular stem cells in forming not only the follicle but also the epidermis. *Cell*. 2000; 102:451–461. [PubMed: 10966107]
- Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, McDowell EP, Lazo-Kallanian S, Williams IR, Sears C, Armstrong SA, Passegue E, DePinho RA, Gilliland DG. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. *Cell*. 2007; 128:325–339. [PubMed: 17254970]
- Trivedi NR, Cong Z, Nelson AM, Albert AJ, Rosamilia LL, Sivarajah S, Gilliland KL, Liu W, Mauger DT, Gabbay RA, Thiboutot DM. Peroxisome proliferator-activated receptors increase human sebum production. *The Journal of investigative dermatology*. 2006; 126:2002–2009. [PubMed: 16675962]
- Tsukada M, Schroder M, Roos TC, Chandraratna RA, Reichert U, Merk HF, Orfanos CE, Zouboulis CC. 13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors. *The Journal of investigative dermatology*. 2000; 115:321–327. [PubMed: 10951254]
- Ubels JL, Veenstra E, Ditlev J, Ingersoll K. Interactions of testosterone and all-trans retinoic acid in regulation of androgen receptor expression in rat lacrimal gland. *Experimental eye research*. 2003; 77:741–748. [PubMed: 14609562]
- Ubels JL, Wertz JT, Ingersoll KE, Jackson RS 2nd, Aupperlee MD. Down-regulation of androgen receptor expression and inhibition of lacrimal gland cell proliferation by retinoic acid. *Experimental eye research*. 2002; 75:561–571. [PubMed: 12457868]
- van der Vos KE, Coffey PJ. The extending network of FOXO transcriptional target genes. *Antioxidants & redox signaling*. 2011; 14:579–592. [PubMed: 20673124]
- White-Chu EF, Reddy M. Dry skin in the elderly: complexities of a common problem. *Clinics in dermatology*. 2011; 29:37–42. [PubMed: 21146730]
- Wolf E, Kahnt E, Ehrlein J, Hermanns W, Brem G, Wanke R. Effects of long-term elevated serum levels of growth hormone on life expectancy of mice: lessons from transgenic animal models. *Mech Ageing Dev*. 1993; 68:71–87. [PubMed: 8350664]
- Yosipovitch G, DeVore A, Dawn A. Obesity and the skin: skin physiology and skin manifestations of obesity. *Journal of the American Academy of Dermatology*. 2007; 56:901–916. quiz 917-920. [PubMed: 17504714]
- Zouboulis CC. Isotretinoin revisited: pluripotent effects on human sebaceous gland cells. *The Journal of investigative dermatology*. 2006; 126:2154–2156. [PubMed: 16983322]
- Zouboulis CC, Adjaye J, Akamatsu H, Moe-Behrens G, Niemann C. Human skin stem cells and the ageing process. *Experimental gerontology*. 2008; 43:986–997. [PubMed: 18809487]

### Highlights


Dry eye disease caused by MGD is prevalent among the elderly population.

Age-related MGD research in humans and animals are reviewed.

Potentially relevant mechanisms for age-related MGD are discussed.


Certain anti-aging reagents including retinoids may promote the development of MGD.

Studies are needed to unravel the mechanism of age-related MGD.




**Figure 1.** Topography of the meibomian glands in the upper and lower eye lids. The drawing depicts a posterior view with the anterior part of the lid removed and the connective tissue made translucent so that the glands are exposed. Reproduced from Springer Science+Business Media: *DER OPHTHALMOLOGE*, Teil I: Anatomie, Embryologie und Histologie der Meibom-Drüsen, volume 106, 2009, page 872-983, Knop N, Knop E, Figure 3, which originated from Sobotta: *Atlas der Anatomie des Menschen* © Elsevier GmbH, Urban & Fischer Verlag München; with kind permission from Elsevier and Springer.





**Figure 2.**

Structural comparison of the meibomian gland in normal state and obstructive MGD. (A) A normal meibomian gland. This section is not cut through the orifice of the central duct (cd). (B) is a magnification of (A) showing the central duct (cd), the connecting ductules (de) and the acini (a). Normally, the ductule (de) is narrow and enters the central duct in an oblique direction. (C–E) Histology section of a meibomian gland with obstructive MGD. (C) The orifice is indicated by the open arrow. The central duct (cd) is partly dilated, with a thinner epithelium wall than in the normal gland. (D) The orifice is obstructed by keratin lamellae which are indicated by small arrows. (E) The ductules (de) are dilated and enter the central duct (cd) at right angles (small arrows). The secretory acini (a) are smaller than in a normal gland, the number of secretory meibocytes is reduced and only a few cell layers remain (arrowhead). Other abnormal structures include: asterisks indicate formations of lumens within the acini, and the double arrowhead indicates the apparent integration of meibocytes of a disrupted acinus into the wall of the central duct. Abbreviations: a, acini; c, ciliary; cd, central duct; conj, conjunctiva mucosa; de, connecting ductules; ep, epidermis; orb, orbicularis muscle; riol, Riolo's muscle. Light microscopic images of paraffin-embedded sections stained with hematoxylin and eosin (H&E); scale bars are shown in the images. Reprinted from Knop E, Knop N, Brewitt H et al. [Meibomian glands, Part III: meibomian gland dysfunction (MGD)—plaidoyer for a discrete disease entity and as an important cause of dry eye.] *Meibom-Dru'sen, Teil III: Meibomdru'sen Dysfunktionen (MGD)—Plaidoyer fu'r ein igensta'ndiges Krankheitsbild und wichtige Ursache fu'r das Trockene Auge. Ophthalmologie. 2009;106:966–979*, Figure 5, with kind permission of Springer Science and Business Media. The legend is adapted from (Knop and others 2011).



**Figure 3.** Hypothetical signaling pathways in meibomian gland cells during aging. Levels of growth factors such as IGF-1 and androgens decline during aging, as well as insulin sensitivity, resulting in cell cycle arrest, apoptosis and reduced lipogenesis, possibly mediated via FOXOs. Increased FOXOs at old age may also keep stem cells in a quiescent state, resulting in less cell turnover of meibomian gland cells. Anti-aging agents such as RA and resveratrol also may influence FOXOs, leading to impaired meibomian gland function.